Advaxis, Inc. (ADXS) EPS Estimated At $-0.43

December 8, 2017 - By Migdalia James

 Advaxis, Inc. (ADXS) EPS Estimated At $ 0.43
Investors sentiment increased to 1.63 in Q2 2017. Its up 0.47, from 1.16 in 2017Q1. It is positive, as 8 investors sold Advaxis, Inc. shares while 19 reduced holdings. 15 funds opened positions while 29 raised stakes. 19.46 million shares or 9.11% less from 21.41 million shares in 2017Q1 were reported.
Vanguard reported 1.78M shares stake. Schwab Charles Inv Management Inc, a California-based fund reported 129,321 shares. Financial Bank Of Montreal Can owns 25,522 shares. Northern Cap Management Lc holds 0.05% or 20,775 shares in its portfolio. Aqr Cap Limited Liability Company holds 0% or 28,171 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Citadel Advsrs Limited Liability Company has 163,997 shares. Vident Inv Advisory Lc holds 0.1% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 187,041 shares. Manufacturers Life Ins Co The accumulated 31,431 shares. Commonwealth Equity Service Incorporated invested in 12,385 shares. Cutler invested in 0.06% or 20,000 shares. Connor Clark And Lunn Inv Management Limited reported 21,375 shares. Wells Fargo Mn reported 44,813 shares. Stonebridge Inc holds 22,605 shares. Deutsche National Bank & Trust Ag, Germany-based fund reported 46,485 shares.

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.43 EPS on January, 8.After having $-0.80 EPS previously, Advaxis, Inc.’s analysts see -46.25 % EPS growth. The stock decreased 0.70% or $0.02 during the last trading session, reaching $2.85. About 436,241 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since December 8, 2016 and is uptrending. It has underperformed by 5.69% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 7 analyst reports since September 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 8 by H.C. Wainwright. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Thursday, July 6 by Cantor Fitzgerald. Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) rating on Monday, June 12. Cantor Fitzgerald has “Buy” rating and $1900 target. Cantor Fitzgerald maintained the shares of ADXS in report on Wednesday, May 31 with “Buy” rating. The rating was initiated by Barclays Capital on Tuesday, September 22 with “Overweight”. The rating was initiated by Guggenheim with “Buy” on Friday, September 11. As per Wednesday, June 14, the company rating was maintained by H.C. Wainwright.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $117.04 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Another recent and important Advaxis, Inc. (NASDAQ:ADXS) news was published by Businesswire.com which published an article titled: “Advaxis to Present at the Jefferies 2017 London Healthcare Conference” on November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.